Retatrutide 60 mg

Retatrutide is an investigational peptide being studied as a triple receptor agonist, targeting the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.

Research involving Retatrutide has focused on its effects on energy balance, appetite regulation, glucose metabolism, insulin sensitivity, lipid metabolism, and body-weight regulation. Its simultaneous activity at three metabolic receptor pathways distinguishes it from single- and dual-receptor agonists.

Human clinical trials have demonstrated substantial effects on body weight and metabolic measures, and Retatrutide continues to be investigated for obesity and related metabolic conditions. It remains an investigational drug and is not currently FDA-approved.

For research use only. Not for human consumption.